Indoleamine 2,3-Dioxygenase in Hematopoietic Stem Cell Transplantation

Author(s): U. Hainz, B. Jurgens, T. Wekerle, M. G. Seidel, Andreas Heitger.

Journal Name: Current Drug Metabolism

Volume 8 , Issue 3 , 2007

Become EABM
Become Reviewer


Hematopoietic stem cell transplantation (HSCT) is complicated by unwelcome side-effects that arise on the basis of an altered immune system. Infectious complications and alloreactive T-cell responses trigger a process of ongoing immune activation and inflammation. Negative-feedback mechanisms to counteract inflammation involve the induction of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO), which mediates anti-inflammatory activities and T-cell inhibition via tryptophan catabolism. However, persistent immune activation and generalized release of pro-inflammatory cytokines deviate immune regulation towards chronic suppression incapable to abrogate the inflammatory response. This review focuses on the unique role of tryptophan catabolism in modulating inflammatory processes and T-cell responses after HSCT.

Keywords: Indoleamine 2,3-dioxygenase, HSCT, T-cell, transplantation, tolerance, inflammation, CTLA4, GVHD

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [267 - 272]
Pages: 6
DOI: 10.2174/138920007780362554
Price: $65

Article Metrics

PDF: 10